BRIEF—OncoSec buys rights from Gaeta Therapeutics

USA-based OncoSec Medical has bought exclusive global rights to a broad portfolio of patents and applications from Gaeta Therapeutics.

OncoSec, which is working on intratumoral gene-delivery immunotherapies, agreed terms for rights covering the combination use of IL-12 DNA and various checkpoint inhibitor therapies.

Chief executive Daniel O'Connor said the rights would give “the freedom to operate using IL-12 in combination with a checkpoint blockade for the treatment of a variety of cancer indications."

"Given the growing body of clinical evidence that this approach has generated, and the revenue implications of protecting downstream checkpoint blockade, we are particularly pleased to license this broad-based IP," he added.